Specialty Pharmacy

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.

Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.

Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.

The tool is designed to address the nocebo effect, which was a concern of prescribers and other health care professionals.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.

Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.

The full results will be published in a peer-reviewed journal and presented at a medical meeting next year as the full results are evaluated.

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

Fabry disease is a rare lysosomal disorder that causes excessive deposition of lipids in tissues.

The treatment is a type IA prodrug of dexamethasone that targets CD206+ macrophages.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.

Investigators presented additional data from a clinical trial at the American College of Rheumatology Convergence, demonstrating similar safety for postmenopausal women with osteoporosis.

The biosimilar is approved for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

Rick C. McCoy, RPh, and Marge McCoy, RPh, combine decades of experience working side by side with a dedication to serving their island community.

Augmentation is a condition in which RLS symptoms intensify or change in response to long-term dopamine agonist treatment.

Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.

This marks the first and only therapy to receive this designation for Sjögren disease, which currently has no approved treatment.

An advanced pharmacy practice experience program between a historically Black university and predominantly White institution impacted student perspectives on cultural competency.

Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.

CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

New technology and innovation may help turn the corner on antibiotic resistance.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

The study investigated faricimab-svoa (Vabysmo) as treatment of diabetic macular edema for patients in racial and ethnic groups that are often underrepresented in trials.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).